In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg 71 over the ®rst 5 days) signi®cantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. The aim of the present analysis was to investigate the eect of Ambroxol treatment on lung function in newborns who developed BPD.
Introduction
Ambroxol, a metabolite of bromhexine with a high anity for lung tissue (1) , is well established in the treatment of respiratory disorders of dierent aetiology. Ambroxol's most important pharmacological activity is mucokinetic and secretolytic, it stimulates synthesis and release of surfactant from type II pneumocytes, and has antioxidative and anti-in¯ammatory eects (2±4). The antioxidative function of Ambroxol has been studied in detail in in vitro investigations by Nowak et al. (5) in cell-free suspensions, and by Gillissen et al. (6) using mononuclear and polymorphonuclear cells.
A large number of preclinical and clinical studies have been performed to investigate the in¯uence of prenatal or postnatal Ambroxol treatment on lung maturation [overview in (1) ]. The results from these studies, however, are inconsistent with regard to the eect of Ambroxol on lung function in the developing lung (7, 8) .
In our previously published clinical trial (9) in preterm newborns 51500 g, the eect of early Ambroxol treatment on the course of the respiratory distress syndrome (RDS) was investigated in a randomized study. The main results of this study were that at day 28 the degree of respiratory support in the Ambroxol group was reduced and the incidence of bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH) and postnatal acquired pneumonia was signi®cantly lower as compared to the control group. No adverse events were seen which could be attributed to the Ambroxol treatment.
In ventilated very low birth weight (VLBW) newborns, the BPD remains the most common pulmonary sequelae in survivors with an incidence of 20±50% depending on the de®nition used for characterization of BPD (10) . The main factors contributing to the development of BPD are structural and functional immaturity (11) , volotrauma (12) , hyperoxia (13) and infections (14) .
In view of its known qualities it was anticipated that early Ambroxol treatment would reduce the incidence of BPD at day 28 and also the degree of the lung function disorders in infants who developed BPD. Therefore, the aim of the present analysis was to investigate the eect of the early Ambroxol treatment on lung function by means of respiratory function testing (RFT) immediately after extubation and at day 28 in infants who ful®lled criteria of BPD (15) .
Materials and methods
The clinical trial was a double-blind parallel group comparison, carried out in the neonatal units of the Humboldt University, Berlin, and the Technical University, Dresden. The clinical trial was reviewed and approved by the Ethics Committees of both hospitals, and informed consent was obtained from parents before randomization.
PATIENT MANAGEMENT
According to the estimated sample size (9), 102 preterm newborns with RDS who had survived day 28 were enrolled in the study. All newborns required mechanical ventilation during the ®rst days of life because of severe respiratory insuciency. Admission criteria were: (i) birthweight 51500 g and a gestational age of 5 34 weeks; (ii) radiological ®ndings consistent with RDS (grading according to Bomsel (16)); (iii) a need for mechanical ventilation and (iv) a need for FIO 2 40Á4 to maintain a Py 2 46Á5 kPa (50 mmHg). Exclusion criteria were (i) positive blood cultures in the umbilical cord blood samples at birth; (ii) major malformations detected after enrolment and (iii) incomplete study protocol. In accordance with the randomized assignment, 52 preterm infants received 30 mg kg 71 bodyweight Ambroxol (Mucosolvan, Dr Karl Thomae Ltd., Biberach) per day during the ®rst 5 days of life and 50 infants received placebo (physiological saline). A blinded vial contained either 2 ml of saline or 15 mg Ambroxol diluted in 2 ml saline. The total daily dose was divided into four individual doses of 7Á5 mg kg 71 and was given as infusion over 5 min every 6 h. No other drugs to improve gas exchange were administered.
RESPIRATORY FUNCTION TESTING
An important consideration in RFT in clinical trials is the choice of suitable tests and devices. In newborns the noninvasive single-breath occlusion technique is commonly used for measurements of lung mechanics. However, this test depends on several requirements (17) e.g. description of lung mechanics using a one compartment model, sucient Herring±Breuer re¯ex, sucient occlusion time for intraalveolar pressure equilibration which cannot be taken for granted in the enrolled patients. To ensure data inclusion, a robust method of data capture was used based on a combination of¯ow-though technique (FTT) and oesophageal manometry.
Measurements of ventilation and lung mechanics were performed at the bedside during tidal breathing as described previously (18) using custom-made equipment. We used a face chamber (FC-100, Siemens-Elema, Sweden) with latex cus that could be altered in line with the body weight for optimal adaptation on the face. The face chamber was continuously rinsed thoroughly with a back-ground¯ow (V' const ). This almost completely eliminated the apparatus dead space and enabled long-term measurements to be taken, even in oxygen-dependent newborns. Flows in and out of the chamber were measured by two screen pneumotachographs (Jaeger, WuÈ rzburg, Germany) and the infant's air¯ow was the dierence between the two signals.
To assess lung mechanics, oesophageal pressure changes were measured using a catheter tip pressure transducer (Messgeraete Werk Zwoentiz, Germany) with a catheter diameter of 1Á4 mm and a pressure transducer diameter of 1Á7 mm at the tip. The catheter was placed in the lower third of the oesophagus in the area of the largest pressure changes. The placement was guided by the volume and pressure signals which were monitored simultaneously. The catheter was passed through the oral cavity downwards to the stomach. A rise in pressure on inspiration con®rmed appropriate placement (Fig. 1 ). The catheter was then drawn back into the oesophagus up to the region of maximal pressure changes and minimal disturbances (e.g. heart activity). The infant was placed supine with the neck in the natural position. They were kept dry and clean and no sedatives were used. RFT was performed about 30 min after feeding. The FIO 2 of the background¯ow was adjusted in accordance with therapeutic requirements. The expiratory background¯ow was always higher than the peak tidal inspiratory¯ow (19) . Calibration of the volume was carried out with the breathing gas used for the measurements.
Following optimal placement of the oesophageal catheter, the infants were allowed to adapt for 5±20 min. The adaptation period is commonly characterized by an initially high variability of the signals and high respiratory frequency. During this adaptation period the respiratory frequency decreases and steady state is reached, charcterized by low respiratory frequency and a more regular breathing pattern.
Depending on the variability of signals, 5±10 artefact-free breathing cycles were evaluated and tidal volume (V T ), respiratory frequency (f) and maximal oesophageal pressure changes (maxP es ) were determined to calculated the lung mechanic parameter (V T /maxP es ). This parameter mainly describes the elastic properties of the lung and is independent from any assumption about lung mechanics (e.g. linear one-compartment model) (18) .
STATISTICAL METHODS
Contingency tables were used to analyse qualitative parameters. The statistical signi®cance was evaluated using the chi squared test or the Fisher exact test (one-tailed) if the cell frequencies in the two by two tables were smaller than ®ve.
For quantitative data, mean and standard deviation (SD) or standard error mean (SEM) were calculated and for their comparison the two-tailed Students t-test was used, provided the data were distributed parametrically. All pulmonary parameters are presented as arithmetic group means with SD in the text and as mean with 95% con®dence intervals in the ®gures. For nonparametric data (e.g. duration of mechanical ventilation), median and range were used and the dierences between groups were investigated using rank tests (Wilcoxon, Mann±Whitney). For statistical evaluation the software STATGRAPHICS (Vers. 3.0, Manugistics Inc., U.S.A.) was used. A level of statistical signi®cance of P50Á05 was accepted.
Results
In the placebo group, 36/50 (72%) infants could be extubated within the ®rst 28 days of life and 13/36 (36%) developed BPD. Simultaneously in the Ambroxol group the number of extubated infants was 44/52 (81%), and 9/44 (20%) developed BPD. As shown in Table 1 in both treatment groups essential patient characteristics in¯uencing the clinical outcome did not dier signi®cantly between the infants with and without BPD, except for the lower gestational age and the higher duration of mechanical ventilation in placebo-treated infants who developed BPD.
RFT AFTER EXTUBATION
Immediately after extubation, respiratory frequency ( Fig. 2 ) and tidal volume ( Fig. 3 ) did not dier signi®cantly between either treatment group and their BPD subgroups. However, in infants treated with Ambroxol, the lung mechanics were slightly improved (pooled data of BPD and non-BPD infants) and the quotient V T /maxP es (Fig. 4 ) was signi®cantly higher (P50Á05) compared to infants treated with placebo. With regard to clinical outcome, in neither treatment group were there statistically signi®cant dierences in lung function between infants with and without BPD at day 28. 
RFT AT DAY 28
Early Ambroxol treatment had no in¯uence on late respiratory function by day 28. Tidal volume (Fig. 3) was increased in all groups (P50Á001) compared to the initial measurements after extubation. The respiratory frequency was also signi®cantly decreased (P50Á05) in infants without BPD, but unchanged in infants with BPD compared to the results after extubation. V T /maxP es (Fig. 4) was only signi®cantly improved (P50Á001) in infants without BPD.
In contrast to RFT after extubation, there were signi®cant dierences between infants with and without BPD at day 28 all measured parameters and these dierences were similar to those in infants with and without Ambroxol treatment. Compared to infants without BPD at day 28 in both treatment groups, the infants with BPD had a signi®cantly higher (P50Á001) respiratory frequency (58Á5+11Á7 min 71 vs. 49Á7+10Á1 min 71 ), a signi®cantly lower (P50Á001) tidal volume (9Á6+1Á9 ml vs. 12Á3+2Á7 ml) and V T /maxP es (8Á9+2Á6 ml kPa 71 vs. 12Á0+2Á9 ml kPa 71 ). 
Discussion
To investigate the eect of early Ambroxol treatment on lung function in BPD infants, we have re-evaluated data of our clinical trial (9) which was carried out in the former GDR at a time when surfactant therapy was not available and the pharmacological eect of the Ambroxol treatment was not in¯uenced by surfactant replacement. This study is unique in the sense that in the future the eects of Ambroxol will probably never again be investigated in this group of untreated RDS patients since surfactant is considered standard treatment for neonatal RDS.
The method of RFT used in this clinical trial (9) is suitable to investigate lung function in VLBW infants (18) . Immediately after extubation, we found that Ambroxol treatment had a moderate eect on lung mechanics, but that this was not detectable by means of ventilatory measurements. In a previous study (18) we showed that in preterm mechanically ventilated newborns the ventilatory parameters were mostly within the normal range after extubation; therefore, large dierences between treatment groups are not to be expected. Furthermore, in this study by modelling an energetic optimal breathing pattern in newborns with RDS we have shown that the sensitivity of tidal breathing parameters is not suciently high to detect small changes in lung mechanics.
In contrast to the ®rst RFTs immediately after extubation, at day 28 there were signi®cant dierences in lung function between infants with and without BPD. In infants with BPD, respiratory frequency was increased and tidal volume reduced. These changes in the tidal breathing pattern are probably caused by impaired lung mechanics, apparent from the signi®cantly reduced V T /maxP es . However, there is no measurable eect of early Ambroxol treatment on the lung function at day 28.
As shown previously, early Ambroxol therapy reduces the incidence of BPD in VLBW infants with established RDS (9) . We speculated that this decrease may have been caused by a reduction of essential BPD risk factors i.e. a reduction in supplemental oxygen, a shorter duration of respiratory support and a lower incidence of infections. The eect of this treatment is explained by an improved supply of surfactant for alveoli and also by the anti-oxidative and anti-in¯ammatory activities of Ambroxol (5, 6) .
However, as in early endotracheal surfactant substitution, in the present study, early Ambroxol treatment showed no in¯uence on lung function in infants with BPD. Contrary to expectation, the introduction of surfactant in the treatment of immature surfactant-de®cient lungs in VLBW infants failed to suciently decrease the incidence of BPD (20±22). Rojas et al. (23) have shown that some of the observed infants, with initially mild respiratory disorders, developed a progressively increased respiratory insuciency with need for mechanical ventilation. This worsening in the clinical course may be caused by a second in¯ammatory disease which develops beyond the ®rst week of life, independent of the initial postnatal cause of respiratory failure (24, 25) . These results are in agreement with the present study in which no signi®cant dierence in the lung function was found immediately after extubation in infants with and without BPD, whereas we found signi®cant dierences in all investigated respiratory parameters at day 28. We speculate that in infants who developed BPD the progressive activity of late in¯ammatory processes damages the lung tissue, leading to impaired lung function at day 28. This may explain the main results of this study, that early Ambroxol therapy reduces the incidence of BPD but has no in¯uence on in¯ammatory processes beyond the ®rst week of life which can lead to BPD.
In the present study, Ambroxol was given over a period of 5 days and a long-term eect cannot be expected. Possibly, the deterioration of lung function in infants who subsequently developed BPD could be reduced by prolonged Ambroxol treatment over a longer period. However, no reports exist about such treatment in preterm infants. The study has shown furthermore that the RFT is a valuable tool for assessment of lung development provided that the equipment is well adapted for measurements in preterm infants.
